Exero reports pivotal xBar data in colorectal surgery

Exero Medical is making the case that post-operative colorectal complications can be caught materially earlier with continuous tissue-level monitoring. The company reported at the American Society of Colon and Rectal Surgeons’ 2026 annual meeting that its investigational xBar system identified anastomotic leaks in colorectal resection patients more than three days earlier, on average, than standard clinical practice. In the 222-patient multicenter pivotal study, Exero said xBar reached 100% sensitivity and 88% specificity by post-operative day 3. (prnewswire.com)

The announcement builds on a development program Exero has been advancing for several years. In a 2024 company update, Exero described xBar as an FDA Breakthrough Device-designated system designed to monitor healing after gastrointestinal surgery using sensors embedded in a standard surgical drain. At that point, the company said an interim 50-patient clinical study suggested the device could detect pending leaks two to three days faster than standard care, and it outlined plans for an international pivotal study across U.S. and Israeli sites. (exeromedical.com)

The new readout suggests the pivotal program expanded beyond those original enrollment expectations. Exero now says the study included 222 patients and that the system analyzes electrophysiological data captured directly from the surgical site to flag impaired healing. According to the company, the technology fits within existing clinical workflows because the sensor is built into a conventional drain rather than requiring a separate invasive monitoring procedure. Exero also said it has submitted the dataset to the FDA as part of a De Novo application and is aiming for U.S. commercialization in 2027, while noting that xBar remains investigational and is not yet approved for sale in the United States. (prnewswire.com)

That pitch lands in an area of real clinical need. Recent reviews describe anastomotic leak as one of the most feared complications in colorectal surgery, with mortality approaching 5% overall in some contemporary summaries and leak rates varying by procedure type, from roughly 3% to 6% in ileocolic anastomoses to 10% to 20% after low colorectal anastomoses. Other literature cited in systematic reviews reports leak incidence around 7.3% in major European audit data, with substantially higher rates in some rectal surgery cohorts. Across sources, the consistent theme is that leak rates have not meaningfully improved despite advances in technique and perioperative care. (academic.oup.com)

Independent expert reaction to this specific 2026 dataset appears limited so far, which is common at the conference-and-press-release stage. Still, Exero’s principal investigator, Dr. Mehraneh Dorna Jafari of Weill Cornell Medicine, framed the value proposition clearly in the company announcement, arguing that detecting a potential leak on day 3 rather than day 6 could change whether a complication remains manageable or becomes life-threatening. That claim is directionally consistent with the broader literature, which emphasizes that leaks drive reoperations, prolonged hospitalization, critical care use, and higher costs. Because the currently available details come primarily from company communications, though, clinicians will likely want to see the full methods, event counts, and peer-reviewed publication before drawing firm conclusions about performance in practice. (prnewswire.com)

Why it matters: For veterinary professionals, this is a useful signal about the future of surgical monitoring, even if the product is built for human colorectal surgery. The important idea is continuous, localized monitoring of healing at the surgical site, rather than relying only on intermittent exams, lab changes, imaging, or visible clinical decline. In referral and specialty practice, especially where GI surgery complications can evolve quickly and after-hours monitoring resources vary, technologies that create earlier warning windows could eventually reshape expectations around post-op surveillance, escalation protocols, and discharge timing. It also fits with a wider movement toward objective, sensor-based recovery data rather than retrospective recognition of complications. (prnewswire.com)

There’s also a regulatory angle worth noting. FDA Breakthrough Device designation can speed interaction with the agency and prioritize review, but it does not mean a device is cleared or approved. FDA says breakthrough designation is meant for devices that may offer more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions, and that marketing authorization still requires the agency’s usual safety and effectiveness standards. Exero’s choice of the De Novo pathway suggests it is positioning xBar as a novel device type without a clear predicate, another sign that the company is trying to establish a new category in post-operative monitoring. (fda.gov)

What to watch: The next milestones are straightforward: whether Exero’s pivotal data appear in a peer-reviewed journal, how the FDA handles the De Novo submission, and whether the company can show similar performance in broader gastrointestinal populations beyond colorectal resection. If those pieces fall into place, xBar could become an early example of surgical-site sensing moving from concept to commercial standard. (prnewswire.com)